Even minimal alteration in peplomer integrity through glycoprotein peroxidation could impair attachment to host cellular membranes foiling viral attachment and penetration.
Minimal residual disease (MRD) as a marker of antileukemic drug efficacy is being used to assess risk status and, in some cases, to adjust the intensity of therapy.